Further investigation showed that NAC treatment significantly inhibited high glucose-induced pulmonary fibrosis in latent TGF-β1-treated A549 cells, implying that high-glucose-derived ROS could activate the latent form of TGF-β1 and eventually lead to A549 cell pulmonary fibrosis. This evidence concerns the gene TGFB1 and pulmonary fibrosis.